Literature DB >> 22869157

The impact of patatin-like phospholipase domain-containing protein 3 polymorphism on hepatocellular carcinoma prognosis.

Yasuto Takeuchi1, Fusao Ikeda, Yuki Moritou, Hiroaki Hagihara, Tetsuya Yasunaka, Kenji Kuwaki, Yasuhiro Miyake, Hideki Ohnishi, Shinichiro Nakamura, Hidenori Shiraha, Akinobu Takaki, Yoshiaki Iwasaki, Kazuhiro Nouso, Kazuhide Yamamoto.   

Abstract

BACKGROUND: The single nucleotide polymorphism (SNP) rs738409 in patatin-like phospholipase domain-containing protein 3 (PNPLA3) is associated with hepatic fat accumulation and disease progression in patients with non-alcoholic fatty liver disease and alcoholic liver disease (ALD). This study was conducted to determine whether PNPLA3 rs738409 SNPs affect development and prognosis of hepatocellular carcinoma (HCC) in patients with various liver diseases.
METHODS: We enrolled 638 consecutive Japanese patients newly diagnosed with HCC between 2001 and 2010: 72 patients with hepatitis B virus (HBV), 462 with hepatitis C virus (HCV), and 104 with non-B non-C (NBNC).
RESULTS: NBNC patients exhibited large tumors of advanced TNM stages at HCC diagnosis, and had significantly poorer prognosis than HBV or HCV patients (P < 0.001 and <0.001, respectively; log-rank test). The G/G genotype of PNPLA3 rs738409 SNP had significantly higher distribution in NBNC patients (P < 0.001) and was significantly associated with higher body mass index (BMI) and an increased aspartate aminotransferase to platelet ratio index. No significant differences were observed in survival with differences in PNPLA3 SNP genotypes among the patients, although ALD patients with the G/G genotype of PNPLA3 SNP and low BMI had significantly poorer survival than those with high BMI (P = 0.028).
CONCLUSIONS: The G/G genotype of PNPLA3 rs738409 SNP was more frequently distributed, and associated with BMI and fibrosis among NBNC-HCC patients but not among HBV or HCV patients. These genotypes might affect HCC prognosis in ALD patients, but not in HBV, HCV, or NAFLD patients.

Entities:  

Mesh:

Substances:

Year:  2012        PMID: 22869157     DOI: 10.1007/s00535-012-0647-3

Source DB:  PubMed          Journal:  J Gastroenterol        ISSN: 0944-1174            Impact factor:   7.527


  36 in total

1.  PNPLA3 variants specifically confer increased risk for histologic nonalcoholic fatty liver disease but not metabolic disease.

Authors:  Elizabeth K Speliotes; Johannah L Butler; Cameron D Palmer; Benjamin F Voight; Joel N Hirschhorn
Journal:  Hepatology       Date:  2010-09       Impact factor: 17.425

2.  A feed-forward loop amplifies nutritional regulation of PNPLA3.

Authors:  Yongcheng Huang; Shaoqing He; John Zhong Li; Young-Kyo Seo; Timothy F Osborne; Jonathan C Cohen; Helen H Hobbs
Journal:  Proc Natl Acad Sci U S A       Date:  2010-04-12       Impact factor: 11.205

Review 3.  Primary liver cancer: worldwide incidence and trends.

Authors:  F Xavier Bosch; Josepa Ribes; Mireia Díaz; Ramon Cléries
Journal:  Gastroenterology       Date:  2004-11       Impact factor: 22.682

4.  Nonalcoholic fatty liver, steatohepatitis, and the metabolic syndrome.

Authors:  Giulio Marchesini; Elisabetta Bugianesi; Gabriele Forlani; Fernanda Cerrelli; Marco Lenzi; Rita Manini; Stefania Natale; Ester Vanni; Nicola Villanova; Nazario Melchionda; Mario Rizzetto
Journal:  Hepatology       Date:  2003-04       Impact factor: 17.425

5.  Adipose triglyceride lipase: function, regulation by insulin, and comparison with adiponutrin.

Authors:  Erin E Kershaw; Jonathan K Hamm; Linda A W Verhagen; Odile Peroni; Masa Katic; Jeffrey S Flier
Journal:  Diabetes       Date:  2006-01       Impact factor: 9.461

6.  Long-term outcomes of cirrhosis in nonalcoholic steatohepatitis compared with hepatitis C.

Authors:  Jason M Hui; James G Kench; Shivakumar Chitturi; Archana Sud; Geoffrey C Farrell; Karen Byth; Pauline Hall; Mahbub Khan; Jacob George
Journal:  Hepatology       Date:  2003-08       Impact factor: 17.425

7.  Evolution of prognostic factors in hepatocellular carcinoma in Japan.

Authors:  K Nouso; Y Kobayashi; S Nakamura; S Kobayashi; J Toshimori; K Kuwaki; H Hagihara; H Onishi; Y Miyake; F Ikeda; H Shiraha; A Takaki; Y Iwasaki; H Kobashi; K Yamamoto
Journal:  Aliment Pharmacol Ther       Date:  2009-10-22       Impact factor: 8.171

8.  A common variant in PNPLA3, which encodes adiponutrin, is associated with liver fat content in humans.

Authors:  A Kotronen; L E Johansson; L M Johansson; C Roos; J Westerbacka; A Hamsten; R Bergholm; P Arkkila; J Arola; T Kiviluoto; R M Fisher; E Ehrenborg; M Orho-Melander; M Ridderstråle; L Groop; H Yki-Järvinen
Journal:  Diabetologia       Date:  2009-02-18       Impact factor: 10.122

9.  Genetic polymorphisms of the human PNPLA3 gene are strongly associated with severity of non-alcoholic fatty liver disease in Japanese.

Authors:  Takahisa Kawaguchi; Yoshio Sumida; Atsushi Umemura; Keitaro Matsuo; Meiko Takahashi; Toshinari Takamura; Kohichiroh Yasui; Toshiji Saibara; Etsuko Hashimoto; Miwa Kawanaka; Sumio Watanabe; Sumio Kawata; Yasuharu Imai; Miki Kokubo; Toshihide Shima; Hyohun Park; Hideo Tanaka; Kazuo Tajima; Ryo Yamada; Fumihiko Matsuda; Takeshi Okanoue
Journal:  PLoS One       Date:  2012-06-14       Impact factor: 3.240

10.  Dissociation between fatty liver and insulin resistance in humans carrying a variant of the patatin-like phospholipase 3 gene.

Authors:  Konstantinos Kantartzis; Andreas Peter; Fausto Machicao; Jürgen Machann; Silvia Wagner; Ingmar Königsrainer; Alfred Königsrainer; Fritz Schick; Andreas Fritsche; Hans-Ulrich Häring; Norbert Stefan
Journal:  Diabetes       Date:  2009-08-03       Impact factor: 9.461

View more
  15 in total

1.  Are genetic variations the most important risk factors for development of hepatocellular carcinoma?

Authors:  Masafumi Ono; Toshiji Saibara
Journal:  J Gastroenterol       Date:  2015-10-31       Impact factor: 7.527

2.  Independent and additive effects of PNPLA3 and TM6SF2 polymorphisms on the development of non-B, non-C hepatocellular carcinoma.

Authors:  Maneerat Raksayot; Natthaya Chuaypen; Apichaya Khlaiphuengsin; Nutcha Pinjaroen; Sombat Treeprasertsuk; Yong Poovorawan; Yasuhito Tanaka; Pisit Tangkijvanich
Journal:  J Gastroenterol       Date:  2018-11-30       Impact factor: 7.527

Review 3.  The effect of PNPLA3 on fibrosis progression and development of hepatocellular carcinoma: a meta-analysis.

Authors:  Amit G Singal; Hema Manjunath; Adam C Yopp; Muhammad S Beg; Jorge A Marrero; Purva Gopal; Akbar K Waljee
Journal:  Am J Gastroenterol       Date:  2014-01-21       Impact factor: 10.864

Review 4.  Is Hepatocellular Cancer the Same Disease in Alcoholic and Nonalcoholic Fatty Liver Diseases?

Authors:  Nicolas Goossens; Yujin Hoshida
Journal:  Gastroenterology       Date:  2016-01-16       Impact factor: 22.682

5.  Genetic variation I148M in patatin-like phospholipase 3 gene and risk of non-alcoholic fatty liver disease among Filipinos.

Authors:  Michael O Baclig; Jingky P Lozano-Kühne; Cynthia A Mapua; Juliet Gopez-Cervantes; Filipinas F Natividad
Journal:  Int J Clin Exp Med       Date:  2014-08-15

6.  The impact of PNPLA3 and JAZF1 on hepatocellular carcinoma in non-viral hepatitis patients with type 2 diabetes mellitus.

Authors:  Misuzu Ueyama; Nao Nishida; Masaaki Korenaga; Keiko Korenaga; Erina Kumagai; Hidekatsu Yanai; Hiroki Adachi; Hisayuki Katsuyama; Sumie Moriyama; Hidetaka Hamasaki; Akahito Sako; Masaya Sugiyama; Yoshihiko Aoki; Masatoshi Imamura; Kazumoto Murata; Naohiko Masaki; Takumi Kawaguchi; Takuji Torimura; Hideyuki Hyogo; Hiroshi Aikata; Kiyoaki Ito; Yoshio Sumida; Akio Kanazawa; Hirotaka Watada; Koji Okamoto; Kenjiro Honda; Kazuyoshi Kon; Tatsuya Kanto; Masashi Mizokami; Sumio Watanabe
Journal:  J Gastroenterol       Date:  2015-09-03       Impact factor: 7.527

7.  PNPLA3 I148M polymorphism, clinical presentation, and survival in patients with hepatocellular carcinoma.

Authors:  Luca Valenti; Benedetta Maria Motta; Giorgio Soardo; Massimo Iavarone; Benedetta Donati; Angelo Sangiovanni; Alessia Carnelutti; Paola Dongiovanni; Raffaela Rametta; Cristina Bertelli; Floriana Facchetti; Massimo Colombo; Silvia Fargion; Anna Ludovica Fracanzani
Journal:  PLoS One       Date:  2013-10-14       Impact factor: 3.240

Review 8.  Molecular mechanisms and new treatment strategies for non-alcoholic steatohepatitis (NASH).

Authors:  Akinobu Takaki; Daisuke Kawai; Kazuhide Yamamoto
Journal:  Int J Mol Sci       Date:  2014-04-29       Impact factor: 5.923

9.  PNPLA3 I148M associations with liver carcinogenesis in Japanese chronic hepatitis C patients.

Authors:  Kazunori Nakaoka; Senju Hashimoto; Naoto Kawabe; Yoshifumi Nitta; Michihito Murao; Takuji Nakano; Hiroaki Shimazaki; Toshiki Kan; Yuka Takagawa; Masashi Ohki; Takamitsu Kurashita; Tomoki Takamura; Toru Nishikawa; Naohiro Ichino; Keisuke Osakabe; Kentaro Yoshioka
Journal:  Springerplus       Date:  2015-02-13

10.  Predictive impact of polymorphism of PNPLA3 on HCC development after interferon therapy in Japanese patients with chronic hepatitis C.

Authors:  Yuki Moritou; Fusao Ikeda; Yoshiaki Iwasaki; Nobuyuki Baba; Kouichi Takaguchi; Tomonori Senoh; Takuya Nagano; Yasuto Takeuchi; Tetsuya Yasunaka; Hideki Ohnishi; Yasuhiro Miyake; Akinobu Takaki; Kazuhiro Nouso; Kazuhide Yamamoto
Journal:  Springerplus       Date:  2013-06-01
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.